Literature DB >> 33954018

Decreased Serum Levels of Interleukin-4 and Interleukin-21 in New Pemphigus Vulgaris Patients, but Not Chronic Patients With Inactive Disease Compared to Healthy Controls.

Pegah Shahbazian1, Maryam Izad2,3, Maryam Daneshpazhooh1, Hossein Mortazavi3, Zahra Salehi2, Shirin Behruzifar1, Soheil Tavakolpour1,4, Arghavan Azizpour1.   

Abstract

BACKGROUND: Pemphigus is a rare group of autoimmune blistering diseases with unknown etiology and unclear pathogenesis. Pemphigus vulgaris (PV) is the most common subtype, and is characterized by ulcerations or flaccid blisters on mucous membranes and on the skin. It is accepted that cytokines have a critical role in the pathogenesis of PV, while their exact roles remain to be elucidated.
OBJECTIVES: This study assessed serum levels of interleukin (IL)-4 and IL-21 in different phases of the disease in comparison with healthy controls.
METHODS: In a case-control cohort design, serum levels of IL-4 and IL-21 were determined by ELISA in three groups: patients with newly diagnosed PV, patients with chronic, inactive PV (PV in remission), and healthy controls.
RESULTS: The study included 88 individuals (58 women and 30 men), including 26 with newly diagnosed PV, 33 with PV in remission, and 29 healthy controls. A significant difference was found among the groups for IL-21 (P = .044), but not for IL-4 (P = .374). Serum levels of IL-4 and IL-21 in newly diagnosed patients were significantly lower than in healthy controls (P = .005 for both), but these cytokine levels in patients with PV in remission were not different from those of controls (P = .343 and P = .221, respectively). Also, no differences in cytokine levels were detected between the newly diagnosed patients and patients with PV in remission. Regardless of disease phase, we detected significantly lower levels of IL-21 in patients than controls (P = .027), but no differences for IL-4 (P = .374).
CONCLUSIONS: IL-4 and IL-21 are involved in PV pathogenesis and disease severity. More studies are required to clarify the role of IL-4 and IL-21 in immunopathogenesis and immune response during PV. ©2021 Shahbazian et al.

Entities:  

Keywords:  ELISA; cytokine; interleukin-21; interleukin-4; pemphigus vulgaris

Year:  2021        PMID: 33954018      PMCID: PMC8060009          DOI: 10.5826/dpc.1102a35

Source DB:  PubMed          Journal:  Dermatol Pract Concept        ISSN: 2160-9381


  24 in total

1.  Cognate Th2-B cell interaction is essential for the autoantibody production in pemphigus vulgaris.

Authors:  Haiqin Zhu; Yayuan Chen; Yun Zhou; Ying Wang; Jie Zheng; Meng Pan
Journal:  J Clin Immunol       Date:  2011-10-19       Impact factor: 8.317

2.  Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus.

Authors:  Soheil Tavakolpour
Journal:  Dermatol Ther       Date:  2016-01-22       Impact factor: 2.851

3.  Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.

Authors:  Dedee F Murrell; Sarah Dick; A R Ahmed; Masayuki Amagai; Maria A Barnadas; Luca Borradori; Jean-Claude Bystryn; Giuseppe Cianchini; Luis Diaz; David Fivenson; Russell Hall; Karen E Harman; Takashi Hashimoto; Michael Hertl; Nico Hunzelmann; Pilar Iranzo; Pascal Joly; Marcel F Jonkman; Yasuo Kitajima; Neil J Korman; Linda K Martin; Daniel Mimouni; Amit G Pandya; Aimee S Payne; David Rubenstein; Hiroshi Shimizu; Animesh A Sinha; David Sirois; Detlef Zillikens; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2008-03-14       Impact factor: 11.527

Review 4.  Single-nucleotide polymorphisms associated with pemphigus vulgaris: Potent markers for better treatment and personalized medicine.

Authors:  HamidReza Mahmoudi; Elaheh Ebrahimi; Maryam Daneshpazhooh; Kamran Balighi; Azin Mirzazadeh; Somayeh Elikaei Behjati; Soheil Tavakolpour
Journal:  Int J Immunogenet       Date:  2019-07-24       Impact factor: 1.466

5.  Study of T helper 1 and T helper 2 responses in pemphigus vulgaris patients receiving interferon alpha 2a injections in addition to a standard protocol therapy: a randomized controlled trial.

Authors:  Mohammad A El-Darouti; Rehab A Hegazy; Rania M Abdel Hay; Marwa S El Hawary; Amira M Tawdy; Marwa M Fawzy; Laila A Rashed
Journal:  Arch Dermatol Res       Date:  2014-12-02       Impact factor: 3.017

Review 6.  Towards personalized medicine for patients with autoimmune diseases: Opportunities and challenges.

Authors:  Soheil Tavakolpour
Journal:  Immunol Lett       Date:  2017-08-08       Impact factor: 3.685

Review 7.  The dual nature of interleukin-10 in pemphigus vulgaris.

Authors:  Michael Jeffrey Cho; Christoph T Ellebrecht; Aimee S Payne
Journal:  Cytokine       Date:  2014-11-22       Impact factor: 3.861

8.  T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals.

Authors:  Christian M Veldman; Kerstin L Gebhard; Wolfgang Uter; Ralf Wassmuth; Joachim Grötzinger; Erwin Schultz; Michael Hertl
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

9.  Increased Frequency of T Follicular Helper Cells and Elevated Interleukin-27 Plasma Levels in Patients with Pemphigus.

Authors:  Tina Hennerici; Robert Pollmann; Thomas Schmidt; Maria Seipelt; Björn Tackenberg; Christian Möbs; Kamran Ghoreschi; Michael Hertl; Rüdiger Eming
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

10.  Analysis of Serum Cytokine Profile in Pemphigus.

Authors:  Sang Hee Lee; Won Jin Hong; Soo-Chan Kim
Journal:  Ann Dermatol       Date:  2017-06-21       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.